OBJECTIVE: Macrophages play a critical role in cerebral aneurysm formation and rupture. The purpose of this study is to demonstrate the feasibility and optimal parameters of imaging macrophages within human cerebral aneurysm wall using ferumoxytol-enhanced MRI. METHODS AND RESULTS: Nineteen unruptured aneurysms in 11 patients were imaged using T2*-GE-MRI sequence. Two protocols were used. Protocol A was an infusion of 2.5 mg/kg of ferumoxytol and imaging at day 0 and 1. Protocol B was an infusion of 5 mg/kg of ferumoxytol and imaging at day 0 and 3. All images were reviewed independently by 2 neuroradiologists to assess for ferumoxytol-associated loss of MRI signal intensity within aneurysm wall. Aneurysm tissue was harvested for histological analysis. Fifty percent (5/10) of aneurysms in protocol A showed ferumoxytol-associated signal changes in aneurysm walls compared to 78% (7/9) of aneurysms in protocol B. Aneurysm tissue harvested from patients infused with ferumoxytol stained positive for both CD68+, demonstrating macrophage infiltration, and Prussian blue, demonstrating uptake of iron particles. Tissue harvested from controls stained positive for CD68 but not Prussian blue. CONCLUSIONS: Imaging with T2*-GE-MRI at 72 hours postinfusion of 5 mg/kg of ferumoxytol establishes a valid and useful approximation of optimal dose and timing parameters for macrophages imaging within aneurysm wall. Further studies are needed to correlate these imaging findings with risk of intracranial aneurysm rupture.
OBJECTIVE: Macrophages play a critical role in cerebral aneurysm formation and rupture. The purpose of this study is to demonstrate the feasibility and optimal parameters of imaging macrophages within humancerebral aneurysm wall using ferumoxytol-enhanced MRI. METHODS AND RESULTS: Nineteen unruptured aneurysms in 11 patients were imaged using T2*-GE-MRI sequence. Two protocols were used. Protocol A was an infusion of 2.5 mg/kg of ferumoxytol and imaging at day 0 and 1. Protocol B was an infusion of 5 mg/kg of ferumoxytol and imaging at day 0 and 3. All images were reviewed independently by 2 neuroradiologists to assess for ferumoxytol-associated loss of MRI signal intensity within aneurysm wall. Aneurysm tissue was harvested for histological analysis. Fifty percent (5/10) of aneurysms in protocol A showed ferumoxytol-associated signal changes in aneurysm walls compared to 78% (7/9) of aneurysms in protocol B. Aneurysm tissue harvested from patients infused with ferumoxytol stained positive for both CD68+, demonstrating macrophage infiltration, and Prussian blue, demonstrating uptake of iron particles. Tissue harvested from controls stained positive for CD68 but not Prussian blue. CONCLUSIONS: Imaging with T2*-GE-MRI at 72 hours postinfusion of 5 mg/kg of ferumoxytol establishes a valid and useful approximation of optimal dose and timing parameters for macrophages imaging within aneurysm wall. Further studies are needed to correlate these imaging findings with risk of intracranial aneurysm rupture.
Authors: Christoph U Herborn; Florian M Vogt; Thomas C Lauenstein; Olaf Dirsch; Claire Corot; Philippe Robert; Stefan G Ruehm Journal: J Magn Reson Imaging Date: 2006-08 Impact factor: 4.813
Authors: Edit Dósa; Suchita Tuladhar; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt Journal: Stroke Date: 2011-04-14 Impact factor: 7.914
Authors: April D Yancy; Alan R Olzinski; Tom C-C Hu; Stephen C Lenhard; Karpagam Aravindhan; Susan M Gruver; Paula M Jacobs; Robert N Willette; Beat M Jucker Journal: J Magn Reson Imaging Date: 2005-04 Impact factor: 4.813
Authors: Juhana Frösen; Anna Piippo; Anders Paetau; Marko Kangasniemi; Mika Niemelä; Juha Hernesniemi; Juha Jääskeläinen Journal: Stroke Date: 2004-08-19 Impact factor: 7.914
Authors: Juhana Frösen; Anna Piippo; Anders Paetau; Marko Kangasniemi; Mika Niemelä; Juha Hernesniemi; Juha Jääskeläinen Journal: Neurosurgery Date: 2006-03 Impact factor: 4.654
Authors: Rikin A Trivedi; Jean-Marie U-King-Im; Martin J Graves; Justin J Cross; Jo Horsley; Martin J Goddard; Jeremy N Skepper; George Quartey; Elizabeth Warburton; Ilse Joubert; Liqun Wang; Peter J Kirkpatrick; John Brown; Jonathan H Gillard Journal: Stroke Date: 2004-05-27 Impact factor: 7.914
Authors: Daniel L Cooke; Diana Bauer; Zhengda Sun; Carol Stillson; Jeffrey Nelson; David Barry; Steven W Hetts; Randall T Higashida; Christopher F Dowd; Van V Halbach; Hua Su; Maythem M Saeed Journal: Interv Neuroradiol Date: 2015-02 Impact factor: 1.610
Authors: Elias Gournaris; Wooram Park; Soojeong Cho; David J Bentrem; Andrew C Larson; Dong-Hyun Kim Journal: ACS Appl Mater Interfaces Date: 2019-06-04 Impact factor: 9.229
Authors: Robert M Starke; Nohra Chalouhi; Dale Ding; Daniel M S Raper; M Sean Mckisic; Gary K Owens; David M Hasan; Ricky Medel; Aaron S Dumont Journal: Transl Stroke Res Date: 2013-10-10 Impact factor: 6.829
Authors: David M Hasan; Nohra Chalouhi; Pascal Jabbour; Vincent A Magnotta; David K Kung; William L Young Journal: J Neuroradiol Date: 2013-02-18 Impact factor: 3.447
Authors: Hushan Yuan; Moses Q Wilks; Marc D Normandin; Georges El Fakhri; Charalambos Kaittanis; Lee Josephson Journal: Nat Protoc Date: 2018-01-25 Impact factor: 13.491
Authors: David M Hasan; Matthew Amans; Tarik Tihan; Christopher Hess; Yi Guo; Soonmee Cha; Hua Su; Alastair J Martin; Michael T Lawton; Edward A Neuwelt; David A Saloner; William L Young Journal: Transl Stroke Res Date: 2012-07 Impact factor: 6.829